MA48625A - Composés et méthodes de traitement de la douleur viscérale - Google Patents

Composés et méthodes de traitement de la douleur viscérale

Info

Publication number
MA48625A
MA48625A MA048625A MA48625A MA48625A MA 48625 A MA48625 A MA 48625A MA 048625 A MA048625 A MA 048625A MA 48625 A MA48625 A MA 48625A MA 48625 A MA48625 A MA 48625A
Authority
MA
Morocco
Prior art keywords
methods
visceral pain
pain treatment
treatment compounds
compounds
Prior art date
Application number
MA048625A
Other languages
English (en)
French (fr)
Inventor
Cheryl Geraldine Lassen
Marcelo Fabian Piccirillo
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA48625A publication Critical patent/MA48625A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA048625A 2017-05-08 2018-05-08 Composés et méthodes de traitement de la douleur viscérale MA48625A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762503280P 2017-05-08 2017-05-08

Publications (1)

Publication Number Publication Date
MA48625A true MA48625A (fr) 2020-03-18

Family

ID=62245468

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048625A MA48625A (fr) 2017-05-08 2018-05-08 Composés et méthodes de traitement de la douleur viscérale

Country Status (13)

Country Link
US (2) US20200078358A1 (https=)
EP (1) EP3621619B1 (https=)
JP (1) JP7247106B2 (https=)
KR (1) KR20200005614A (https=)
CN (1) CN110709085A (https=)
AU (1) AU2018266145A1 (https=)
BR (1) BR112019023214A2 (https=)
CA (1) CA3062824A1 (https=)
EA (1) EA201992638A1 (https=)
ES (1) ES2956059T3 (https=)
MA (1) MA48625A (https=)
MX (2) MX2019013311A (https=)
WO (1) WO2018208848A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
CA3212135A1 (en) * 2021-03-02 2022-09-09 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
TW202330496A (zh) * 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法
US20250387335A1 (en) * 2022-02-02 2025-12-25 Makscientific, Llc Pharmaceutical Compositions, and Preparation and Methods of Use Thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605906A (en) 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5971080A (en) 1997-11-26 1999-10-26 Central Sprinkler Corporation Quick response dry pipe sprinkler system
US7308894B2 (en) 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
IL150302A (en) 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
JP2008505965A (ja) 2004-07-12 2008-02-28 カディラ ヘルスケア リミティド カンナビノイド受容体修飾因子としての三環式ピラゾール誘導体
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2613678A1 (en) 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7597910B2 (en) 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
WO2007035945A1 (en) 2005-09-23 2007-03-29 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
PT2081572E (pt) 2006-07-04 2010-05-17 Janssen Pharmaceutica Nv Agonistas de canabinóides de benzimidazolo com um grupo heterocíclico substituído
CA2664310A1 (en) 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
WO2008053341A2 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
WO2008064054A2 (en) 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
EP2170350B1 (en) 2007-06-21 2013-09-11 Cara Therapeutics, Inc. Substituted imidazoheterocycles
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
KR101787116B1 (ko) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
CA2770866C (en) 2009-08-28 2017-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
US9458136B2 (en) * 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US9597340B2 (en) * 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2016085941A1 (en) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
WO2017039643A1 (en) 2015-09-01 2017-03-09 Arena Pharmaceuticals, Inc. Cb2 receptor internalization
CA3019842A1 (en) * 2016-04-10 2017-10-19 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
WO2018208847A1 (en) * 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
EP3684353A4 (en) * 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
CA3212135A1 (en) * 2021-03-02 2022-09-09 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
TW202330496A (zh) * 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Also Published As

Publication number Publication date
AU2018266145A1 (en) 2019-11-28
MX2022008265A (es) 2022-08-04
EA201992638A1 (ru) 2020-03-18
MX2019013311A (es) 2020-08-03
BR112019023214A2 (pt) 2020-05-26
CN110709085A (zh) 2020-01-17
EP3621619B1 (en) 2023-06-28
EP3621619A1 (en) 2020-03-18
ES2956059T3 (es) 2023-12-12
US20230033510A1 (en) 2023-02-02
US12201633B2 (en) 2025-01-21
US20200078358A1 (en) 2020-03-12
JP2020518649A (ja) 2020-06-25
CA3062824A1 (en) 2018-11-15
KR20200005614A (ko) 2020-01-15
WO2018208848A1 (en) 2018-11-15
JP7247106B2 (ja) 2023-03-28
EP3621619C0 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
EP3813808A4 (en) Methods of treating substance abuse
MA46102A (fr) Composés de tétracycline et méthodes de traitement
EP3607072A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR PHENYLKETONURIA
EP3613073A4 (en) DIE TREATMENT
EP3645121A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
EP3448504A4 (en) BRAIN STIMULATION TREATMENT FOR DEPRESSION
EP3589659A4 (en) COMPOUNDS AND USES FOR TREATMENT OF CANCER
EP3370721A4 (en) TREATMENT OF OSTEOARTHRITIS
EP3658139A4 (en) Methods for treating liver diseases
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
EP3946345A4 (en) METHODS OF TREATMENT OF NEUROPATHIC PAIN
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3630101A4 (en) METHODS OF TREATMENT OF FIBROTIC DISEASES
EP3752161A4 (en) METHOD OF TREATMENT OF FIBROSE
EP3606531A4 (en) METHOD OF TREATMENT OF CANCER
EP3773633A4 (en) METHODS OF TREATMENT OF GLIOBLASTOMA
EP3634422A4 (en) METHOD FOR TREATMENT OF LEUCODYSTROPHIES
EP3745862A4 (en) METHOD OF TREATMENT OF FIBROTIC DISEASES
EP3599983A4 (en) ENDOSCOPES AND TREATMENT PROCEDURES
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
EP3313417A4 (en) METHOD FOR TREATING AUTOIMMUNE AND ALLOIMMUNE DISEASES
EP3383857A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
IL270900A (en) Treatment of cutaneous disorders
MA46353A (fr) Méthodes de traitement de l'infertilité féminine